3.57
+0.0056(+0.16%)
Currency In USD
| Previous Close | 3.56 |
| Open | 3.56 |
| Day High | 3.59 |
| Day Low | 3.48 |
| 52-Week High | 5.89 |
| 52-Week Low | 1.95 |
| Volume | 53,302 |
| Average Volume | 130,248 |
| Market Cap | 134.68M |
| PE | -4.19 |
| EPS | -0.85 |
| Moving Average 50 Days | 3.17 |
| Moving Average 200 Days | 3.1 |
| Change | 0.01 |
If you invested $1000 in Genelux Corporation (GNLX) since IPO date, it would be worth $579.77 as of August 18, 2025 at a share price of $3.566. Whereas If you bought $1000 worth of Genelux Corporation (GNLX) shares 1 year ago, it would be worth $1,706.03 as of August 18, 2025 at a share price of $3.566.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
GlobeNewswire Inc.
Jul 07, 2025 11:00 AM GMT
WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference
GlobeNewswire Inc.
May 01, 2025 8:05 PM GMT
WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, CFO, wil
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
GlobeNewswire Inc.
Mar 25, 2025 12:31 PM GMT
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3,000,000 shares of its common st